cabozantinib
Natco,India
$133.00-
SelectSpecification/Number
-
ParameterDetailed information
-
NoticeCustoms clearance instructions
-
Required readingConsumption notice
- Description
- Information
INDICATIONS AND USAGE(适应症)
Renal Cell Carcinoma
CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC.
Hepatocellular Carcinoma
CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Differentiated Thyroid Cancer
CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
DOSAGE(服用剂量)
Important Dosage Information
·Stop treatment with CABOMETYX at least 3 weeks prior to scheduled surgery, including dental surgery.
·Do not substitute CABOMETYX tablets with cabozantinib capsules.
Recommended Dosage for Renal Cell Carcinoma
The recommended dosage of CABOMETYX as a single agent is 60 mg once daily until disease progression or unacceptable toxicity administered as recommended.
The recommended dosage of CABOMETYX in combination with nivolumab is provided in the following table:
Recommended Dosage for Hepatocellular Carcinoma
The recommended dosage of CABOMETYX as a single agent is 60 mg once daily until disease progression or unacceptable toxicity administered as recommended.
Recommended Dosage for Differentiated Thyroid Cancer
The recommended dosage of CABOMETYX as a single agent for adult and pediatric patients 12 years of age and older with BSA greater than or equal to 1.2 m2 is 60 mg once daily until disease progression or unacceptable toxicity administered as recommended.
The recommended dosage of CABOMETYX as a single agent in pediatric patients 12 years of age and older with BSA less than 1.2 m2 is 40 mg once daily until disease progression or unacceptable toxicity administered as recommended.
ADVERSE REACTIONS(不良反应)
Hemorrhage
Perforations and Fistulas
Thrombotic Events
Hypertension and Hypertensive Crisis
Diarrhea
Palmar-plantar Erythrodysesthesia
Hepatotoxicity
Adrenal Insufficiency
Proteinuria
Osteonecrosis of the Jaw
Impaired Wound Healing
Reversible Posterior Leukoencephalopathy Syndrome
Thyroid Dysfunction
Hypocalcemia
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/3850cce2-6137-42e5-a792-d318c4a4b3b5/spl-doc?hl=Cabozantinib
cabozantinibinformation
No information yet!!!